Phase I/II trial of vandetanib and bortezomib in adults with locally advanced or metastatic medullary thyroid cancer: Phase I results.

被引：3
|
作者：
Gramza, A. W. [1 ]
Wells, S. A. [1 ]
Balasubramaniam, S. [1 ]
Fojo, A. T. [1 ]
机构：
[1] NCI, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.5565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5565
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer
    Del Rivero, Jaydira
    Edgerly, Maureen
    Ward, Jean
    Madan, Ravi A.
    Balasubramaniam, Sanjeeve
    Fojo, Tito
    Gramza, Ann W.
    ONCOLOGIST, 2019, 24 (01): : 16 - +
  • [2] Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
    Wells, Samuel A., Jr.
    Robinson, Bruce G.
    Gagel, Robert F.
    Dralle, Henning
    Fagin, James A.
    Santoro, Massimo
    Baudin, Eric
    Elisei, Rossella
    Jarzab, Barbara
    Vasselli, James R.
    Read, Jessica
    Langmuir, Peter
    Ryan, Anderson J.
    Schlumberger, Martin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) : 134 - 141
  • [3] Phase I/II trial of vandetanib in children and adolescents with hereditary medullary thyroid carcinoma
    Fox, E.
    Widemann, B. C.
    Whitcomb, P. O.
    Aikin, A.
    Dombi, E.
    Lodish, M.
    Stratakis, C. A.
    Steinberg, S.
    Wells, S. A., Jr.
    Balis, F. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer
    Haddad, R. I.
    Krebs, A. D.
    Vasselli, J.
    Paz-Ares, L. G.
    Robinson, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] A PHASE II STUDY OF VANDETANIB IN METASTATIC HEREDITARY MEDULLARY THYROID CANCER
    Paz-Ares, L.
    Haddad, R.
    Krebs, A. D.
    Vasselli, J.
    Robinson, B.
    ANNALS OF ONCOLOGY, 2008, 19 : 247 - 247
  • [6] VANDETANIB IN LOCALLY ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC): A RANDOMIZED, DOUBLE-BLIND PHASE III TRIAL (ZETA)
    Wells, S. A.
    Robinson, B. G.
    Gagel, R. F.
    Dralle, H.
    Fagin, J. A.
    Santoro, M.
    Baudin, E.
    Vasselli, J.
    Read, J.
    Schlumberger, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 315 - 315
  • [7] Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial
    Wells, S. A., Jr.
    Gosnell, J. E.
    Gagel, R. F.
    Moley, J. F.
    Pfister, D. G.
    Sosa, J. A.
    Skinner, M.
    Krebs, A.
    Hou, J.
    Schlumberger, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
    Wells, Samuel A., Jr.
    Gosnell, Jessica E.
    Gagel, Robert F.
    Moley, Jeffrey
    Pfister, David
    Sosa, Julie A.
    Skinner, Michael
    Krebs, Annetta
    Vasselli, James
    Schlumberger, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (05) : 767 - 772
  • [9] Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
    Leboulleux, Sophie
    Bastholt, Lars
    Krause, Thomas
    de la Fouchardiere, Christelle
    Tennvall, Jan
    Awada, Ahmad
    Manuel Gomez, Jose
    Bonichon, Francoise
    Leenhardt, Laurence
    Soufflet, Christine
    Licour, Muriel
    Schlumberger, Martin J.
    LANCET ONCOLOGY, 2012, 13 (09): : 897 - 905
  • [10] VANDETANIB IN LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (PAPILLARY OR FOLLICULAR; DTC): A RANDOMIZED, DOUBLE-BLIND PHASE II TRIAL
    Leboulleux, S.
    Bastholt, L.
    Krause, T. M.
    De La Fouchardiere, C.
    Tennvall, J.
    Awada, A.
    Gomez, J. M.
    Carrasco, A. Tisseron
    Licour, M.
    Schlumberger, M. J.
    ANNALS OF ONCOLOGY, 2010, 21 : 315 - 315
12345